Value proposition

TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.

NSKI, ulcerative colitis, kinase inhibitors, and ophthalmology